Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shawna Schmidt

Pain Medicine Aberdeen, SD Medical Doctor

NPI 1770603888 CMS profile 125289

815 1St Ave Se, Aberdeen, SD 57401

Open in the dashboard

General payments

$5,327

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shawna Schmidt of Aberdeen, SD is reported in the CMS Open Payments database as having received $5,327 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53 2
2023 General $57 3
2022 General $3,137 23
2021 General $2,016 19
2019 General $64 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shawna Schmidt
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Shawna Schmidt were reported at $53. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Shawna Schmidt Pain Medicine median Middle half National median
2019 $64 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $2,016 $399 $112–$1,219 $132
2022 $3,137 $455 $137–$1,484 $149
2023 $57 $484 $128–$1,495 $160
2024 $0 $498 $131–$1,540 $164
2025 $53 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $5,112 39 payments
  2. AbbVie, Inc. $115 6 payments
  3. Amgen Inc. $28 1 payment
  4. Vertex Pharmaceuticals Incorporated $21 1 payment
  5. Lundbeck LLC $15 1 payment
  6. Nevro Corp. $13 1 payment
  7. Pfizer Inc. $12 1 payment
  8. Supernus Pharmaceuticals, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,150 19 payments
  2. Food and Beverage $1,178 32 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMEDII $2,247 20 payments
  2. Vanta $1,072 9 payments
  3. RESTORESENSORSURESCAN $874 2 payments
  4. SYNCHROMED $871 6 payments
  5. UBRELVY $74 4 payments
  6. BOTOX $42 2 payments
  7. INCEPTIV $32 1 payment
  8. AIMOVIG $28 1 payment
  9. JOURNAVX $21 1 payment
  10. VYEPTI $15 1 payment
  11. Other $51 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,526

Median for Anesthesiology: 322

Drug cost

$127,986

Median for Anesthesiology: $8,738

Branded share of claims

31.5%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 21 $21,633
Nucynta Tapentadol Hcl Brand 22 $20,384
Oxycontin Oxycodone Hcl Brand 32 $17,416
Aimovig Autoinjector Erenumab-Aooe Brand 13 $9,905
Butrans Buprenorphine Brand 16 $8,637
Lyrica Pregabalin Brand 13 $8,083
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 363 $7,043
Fentanyl Generic 51 $6,761
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 150 $3,086
Gabapentin Generic 320 $3,034

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$98,706

Medicare's payments for the services billed

Medicare patients

472

Average age 73

Services billed

2,249

282 women, 190 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Depression 32%
Diabetes 30%
Ischemic heart disease 28%
Chronic kidney disease 26%
COPD 23%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record